Anti-Mouse CD153 – Purified in vivo PLATINUM™ Functional Grade

Clone RM153, a rat anti-mouse monoclonal antibody targeting CD153 (CD30 ligand, CD30L), is commonly used in vivo in mice to block CD30/CD30L interactions and assess the roles of this pathway in immune regulation and disease models. Its major in vivo applications leverage its ability to inhibit CD30L function, sometimes deplete CD30L⁺ cells, and potentially induce reverse signaling.

Key in vivo uses and disease models include:

• Autoimmunity: RM153 can prevent or delay the onset of type 1 diabetes in non-obese diabetic (NOD) mice when administration starts early in life. It is also used to block diabetes transfer by NOD splenocytes into immunodeficient NOD-SCID mice.
• Graft-versus-host disease (GVHD): Treatment with RM153 prolongs survival in models of CD4⁺ T cell-mediated lethal GVHD by disrupting CD30/CD30L interactions.
• Transplant models: In allograft rejection (skin graft model), RM153 blocks the ability of regulatory T cells to delay graft rejection, elucidating the CD30/CD30L axis in immune regulation.
• Infectious disease: In mice infected with Mycobacterium avium, anti-CD30L RM153 treatment altered bacterial burdens at later stages of infection, highlighting roles in long-term immune control.
• Depletion studies: At sufficient doses, RM153 can deplete CD30L⁺ cells in vivo, especially in transgenic mice with high CD30L expression, although depletion is harder to detect in normal mice due to limited and transient CD30L expression.

Additional in vivo applications may include:

• Blocking ligand binding in T cell function studies.
• Investigating costimulation and immune activation pathways, given CD153's role in stimulating B cell and T cell functions.
• Studies of lymphoma or immune activation, since CD30/CD30L signaling is involved in lymphoid cell proliferation and certain lymphomas.

RM153 is also employed in mechanistic studies to dissect immune signaling, cell-cell interactions, and cytokine-mediated effects in murine models.

In summary, the most common in vivo applications of RM153 in mice are blocking CD30/CD30L signaling to modulate autoimmunity (type 1 diabetes), allograft rejection, GVHD, and chronic infection models, as well as used occasionally for depletion of CD30L⁺ cells and studying T/B cell costimulatory pathways.

Commonly used antibodies or proteins in conjunction with RM153 (an anti-mouse CD153 monoclonal antibody) include those targeting CD3, CD28, and CD30, as well as markers for T cell subsets such as CD4 and T helper cytokines.

Key combinations in literature:

• RM153 and anti-CD3: Used to stimulate and analyze activation of murine T cells. Anti-CD3 is a standard antibody for T cell receptor engagement, essential for activating T cells in vitro.
• RM153 and anti-CD28: This costimulatory antibody is frequently paired with anti-CD3 to evaluate proliferation and functional responses in T cell subsets.
• RM153 and anti-CD30: As CD30 is the receptor for CD153, studies often assess the expression of both, sometimes using antibodies against CD30 for flow cytometry or functional assays to investigate interactions.
• T cell subset markers (CD4, Th1/Th2 cytokines): Studies characterize CD153 or CD30 expression on CD4⁺ T cells, and often use intracellular cytokine staining or surface markers to distinguish Th1 and Th2 populations after activation.

Summary Table: Commonly Combined Antibodies/Proteins with RM153

While other articles mention RM153 use, most functional studies focus on T cell activation contexts: anti-CD3 and anti-CD28 are the most frequently paired antibodies. For flow cytometric or sorting purposes, lineage markers such as anti-CD4 are also common. Research can also use RM153 together with anti-CD30 to block or modulate CD30-CD153 interactions.

Studies of B cell function may also involve immunoglobulin markers, though these are less commonly detailed in the context of RM153. In sum, anti-CD3, anti-CD28, anti-CD30, and T cell markers are the principal antibodies or proteins used with RM153 in the immunological literature.

Key findings from scientific literature citing clone RM153 focus on its use as a tool for detecting and depleting CD153 (CD30 Ligand) in mice, with several experimental and immunological insights directly attributed to its application.

• Detection and Depletion of CD153-Expressing Cells: Clone RM153, a rat IgG2b monoclonal antibody, is widely cited for its ability to recognize mouse CD153 in flow cytometry and tissue studies. Research shows that anti-CD153 (clone RM153) can selectively deplete CD153-expressing T cells, notably in aging studies, enabling detailed investigation of their functional roles in immune aging and disease.

• Functional Studies in Immunology: Studies using clone RM153 have demonstrated the importance of CD153 signaling in age-associated tertiary lymphoid tissue (TLT) formation and chronic inflammation. For instance:

  • One study utilized CD153-deficient mice (as well as functional blockade using clone RM153) to show that CD153/CD30 interactions promote the development of TLT and influence immune cell composition in aged, injured tissues.
  • Blockade or depletion of CD153 with RM153 affects the abundance and phenotype of senescence-associated T (SAT) cells and germinal center B cells, leading to altered immune responses in aged organs.

• Role in Humoral Immunity: Literature reviews highlight that clone RM153 was crucial in proving that CD153-CD30 interactions affect B cell and T cell function, especially for understanding humoral immunity pathways. Experimental interventions with this clone revealed modulation of antibody responses and germinal center architecture.

• Standard for CD153 Identification and Reference: Clone RM153 is referenced as a benchmark reagent for anti-mouse CD153 applications, with validated use across flow cytometry, immunofluorescence, and in vivo depletion protocols in immunological research.

When citing clone RM153 in scientific publications, include the antibody’s clone designation, supplier catalog number, and validated applications to ensure reproducibility.

In summary, clone RM153 is a central reagent in mouse immunology for dissecting CD153’s role in aging, humoral immunity, and lymphoid tissue formation, especially via selective detection and functional depletion of CD153-expressing cells.

Dosing regimens for clone RM153—an anti-CD30L (CD153L) monoclonal antibody—vary by mouse strain and disease model, but published data most thoroughly describe its use in NOD (Non-Obese Diabetic) mice for autoimmune and diabetes studies.

NOD Mouse Model Regimens:

• Dose: 500 µg (micrograms) of RM153 per injection.
• Route: Intraperitoneal (i.p.) injection.
• Schedule and Duration:
  • Injected twice weekly.
  • Administered over different periods:
    • From 2–10 weeks of age or
    • From 4–10 weeks of age.

This regimen was designed to span critical windows in disease development. Both the full-length RM153 IgG and its F(ab')₂ fragment were tested, with the F(ab')₂ fragment used at equivalent dosing for mechanistic studies.

Degree of Model-Specific Variation:

• The literature survey did not identify published regimens for other mouse strains or disease models (e.g., C57BL/6, BALB/c, or tumor models) using RM153.
• Dosing frequency (twice weekly) and administration route (i.p.) were constant across NOD studies, but other models may warrant adaptation due to distinct pharmacodynamics and immune environments.
• General in vivo antibody dosing guides suggest similar monoclonal antibody doses (100–500 µg) and schedules (every 3–4 days, i.p.) are effective for different immunological targets in various mouse strains. However, these are not specific to RM153.

Essential Details and Considerations:

• RM153 was compared with control IgG for both dose window and disease outcome evaluation in NOD mice.
• The effects of RM153 were measured via endpoints such as diabetes incidence and degree of insulitis (pancreatic inflammation), demonstrating efficacy differences dependent on duration and timing of dosing.
• No evidence from the retrieved literature indicates dosing in other mouse models or adjustment for different ages or disease conditions; extrapolation should be confirmed with pilot titrations.

Summary Table (NOD Mouse Dosing, RM153):

If information is needed for models other than NOD mice, experimental determination or unpublished protocols may be required, as no mouse-strain-specific RM153 dosing variations were found in standard references or recent peer-reviewed studies.